



(51) International Patent Classification:

A61K 39/108 (2006.01) A61P 13/02 (2006.01)
A61P 31/04 (2006.01)

(21) International Application Number:

PCT/IB2022/062232

(22) International Filing Date:

14 December 2022 (14.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/290,895 17 December 2021 (17.12.2021) US
63/384,607 22 November 2022 (22.11.2022) US

(71) Applicant: PFIZER INC. [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **CHE, Ye**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **CHORRO, Laurent Olivier**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **DIAZ, Fernando Martin**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **DONALD, Robert George Konrad**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **LI, Jin**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **SILMON DE MONERRI, Natalie Clare**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **SIMON, Raphael**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF

FIG. 1



(57) **Abstract:** The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E.coli infection, including urinary tract infection.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*